Related Experiment Videos
Aspirin in cardiovascular disease
Insights
Aspirin, a common drug, is now recognized for its surprising chemo-preventive capabilities, particularly in reducing cancer risk. Ongoing research aims to solidify its role in cancer prevention and treatment strategies.
Area of Science:
- Pharmacology
- Oncology
- Preventive Medicine
Background:
- Aspirin's historical development as a therapeutic agent.
- The evolving understanding of aspirin's applications beyond pain relief.
- The drug's established role in acute myocardial infarction (AMI) emergency treatment.
Purpose of the Study:
- To review the use of aspirin as a primary and secondary chemo-preventive agent.
- To explore aspirin's potential in cancer prevention and treatment, including colon cancer.
- To highlight the surprising modern-day therapeutic uses of aspirin.
Main Methods:
- Review of historical data on aspirin's therapeutic uses.
- Analysis of current research on aspirin's chemo-preventive properties.
- Examination of clinical evidence supporting aspirin in cancer and cardiovascular emergency care.
Main Results:
- Aspirin demonstrates significant potential as a chemo-preventive agent.
- Evidence suggests efficacy in preventing and potentially treating colon cancer and other malignancies.
- Aspirin is a crucial component in emergency treatment protocols for AMI.
Conclusions:
- Aspirin's utility as a chemo-preventive agent is increasingly recognized.
- Further studies are expected to define aspirin's precise role in cancer prevention.
- The historical perspective underscores the importance of continued evaluation of established drugs like aspirin.
Abstract:
The historic genesis of aspirin as a therapeutic agent is discussed. The use of aspirin as a primary and secondary chemo-preventive agent is reviewed. Those who introduced aspirin in the late 19th century would be surprised by the uses of aspirin today. It is anticipated that existing and further studies on the use of aspirin as a primary preventive agent will establish its utility and a more precise niche for it as a chemo-preventive agent. Reports indicate that it may be useful as a chemo-preventive agent in the prevention and possibly in the treatment of cancer of the colon and other malignancies. This plebeian drug, aspirin, has earned a position, some would say an egalitarian position, along with thrombolysis and primary coronary angioplasty in the emergency treatment of AMI. There are those who would add an intravenous beta blocker and an ACE inhibitor to this regimen. The laborious history of aspirin should again remind clinicians that they should continue to heed the admonition of Alexander Pope when he asserted, "Be not the first by whom the new is tried nor yet the last to lay the old aside."